CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.

J Transl Med · 2015 · PMC4389307 · PMID 25890004

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

borderline significancep = 0.052so close (0.05 < p ≤ 0.1)

Statistical analysis revealed borderline significance (p = 0.052) for this association.

also in 4,324 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.